Crossmark

: Axel Finckh received consulting fees from AbbVie, AstraZeneca, Bristol Myers Squibb, Eli Lilly, MSD and Pfizer, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AbbVie, Bristol Myers Squibb, Eli Lilly, MSD and Pfizer, and grants or contracts from Bristol Myers Squibb, Eli Lilly, Galapagos and Pfizer. Cécile Tremblay received consulting fees from AbbVie, AstraZeneca, Gilead, GlaxoSmithKline, Medicago, Merck, Moderna, Novovax, and VIIV, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Gilead, GlaxoSmithKline, Merck, Moderna, Pfizer, and Sanofi, participation on a data safety monitoring board or advisory board for DalCor Pharmaceuticals, hespiridin, and Takeda Pharmaceuticals, and received grants or contracts from CIHR, Réseau FRQS SIDAMI, Gilead, Merck, and National Institutes of Health. Christoph D Spinner received grants, personal fees from AbbVie, AstraZeneca, BioNtech, Eli Lilly, GlaxoSmithKline, Formycon, Molecular partners, MSD, Pfizer, Roche, Shionogi, SOBI (during the conduct of the study) and Synairgen, personal fees and non-financial support from B. Braun Melsungen, grants, personal fees and non-financial support from Gilead Sciences, grants and personal fees from Janssen-Cilag, MSD, and ViiV Healthcare, outside the submitted work, other from Apeiron and Eli Lilly, and grants from Cepheid. Hermann Einsele has nothing to disclose. Christopher J Edwards received consulting fees from AbbVie, AstraZeneca, Gilead, GlaxoSmithKline, Eli Lilly, and AbbVie, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AbbVie, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Pfizer, Roche, and Sandoz, received support for attending meetings and/or travel from Eli Lilly and is a Chair of EULAR Education Committee. Dominique Bertrand has nothing to disclose. Gkikas Magiorkinis received payment or honoraria from Gilead Sciences and Roche; support for attending meetings and/or travel from AstraZeneca, and participation on a data safety monitoring board or advisory board from AstraZeneca and GlaxoSmithKline. Igor Aurer received consulting fees, payment or honoraria, support for attending meetings/travel fees and participation on a data safety monitoring board or advisory board for AstraZeneca and Roche, chairman of KroHem—Croatian Cooperative Group for Hematologic Diseases, and board member of Croatian Society for Hematology. Jacques-Eric Gottenberg received consulting fees from AbbVie and AstraZeneca, and received grants or contracts from AbbVie, Eli Lilly, and Pfizer. Loreto Gesualdo received consulting fees from AstraZeneca, Baxter, Chinook, Estor, GlaxoSmithKline, Medtronic, Mundipharma, Novartis, Pharmadoc, Roche, Sandoz, Sanofi, and Travere, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Astellas, AstraZeneca, Estor, Fresenius, Novartis, Travere, and Werfen, received support for attending meetings and/or travel from Takeda Pharmaceuticals, participation on a data safety monitoring board or advisory board for AstraZeneca, Baxter, Chinook, Estor, GlaxoSmithKline, Medtronic, Mundipharma, Novartis, Pharmadoc, Roche, Sandoz, Sanofi, and Travere, and grants or contracts from Abionyx and Sanofi. Michel Goldman received consulting fees from AstraZeneca for Revive Committee, and leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid from ABOLERIS company, Davos Alzheimer Collaboration, SANTERO company and Tuberculosis Vaccine Initiative. Odile Launay received consulting fees from AstraZeneca, GlaxoSmithKline, Moderna, MSD, Sanofi, and Sequirus, payment or honoraria for educational events from AstraZeneca, GlaxoSmithKline, and Sanofi, participation on a data safety monitoring board or advisory board for Sanofi, and received contracts from AstraZeneca to perform clinical trials. Samira Bell received consulting fees from AstraZeneca and GlaxoSmithKline, participation on a data safety monitoring board or advisory board for AstraZeneca, and received all support for the present manuscript from AstraZeneca. Zain Chagla received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Gilead, GlaxoSmithKline, Merck, Moderna, Pfizer, and Roche, and grants or contracts from Gilead, Merck, Pfizer, and Roche for research support. Carolina Casañas i Comabella, Samantha James, and Katarzyna Borkowska are employees of Evidera. Evidera received funding from AstraZeneca to conduct literature review supporting the manuscript content. Cécile Artaud, Fungwe Jah, Sabada Dube, and Sofie Arnetorp are employees of AstraZeneca and hold or may hold stock. Renata T C Yokota received consulting fees from AstraZeneca. Walid Kandeil was an employee of AstraZeneca at time of study, and holds or may hold stock.

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

Document is current

Any future updates will be listed below